Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2024-09-25 Share Issue/Capital Cha…
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
Lifecare ASA: Re-purchase of shares and warrants
Share Issue/Capital Change Classification · 1% confidence The document explicitly states its purpose: "Lifecare ASA: Re-purchase of shares and warrants". It details the company's plan to repurchase shares and warrants to facilitate a 13:1 consolidation ratio for shareholders whose holdings do not divide evenly. This action—the company buying back its own shares/warrants—directly corresponds to the definition of 'Transaction in Own Shares' (POS). The document is short and is an announcement of a specific corporate action, not a comprehensive report like a 10-K or IR.
2024-09-25 English
Minutes from Extraordinary General Meeting
AGM Information Classification · 1% confidence The document is explicitly titled "MINUTES FROM EXTRAORDINARY GENERAL MEETING" held on 17 September 2024. This document records the outcomes of a shareholder meeting where proposals were adopted. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it is an Extraordinary General Meeting (EGM), the content (minutes and adopted proposals) fits best under the AGM-R category, as there is no specific EGM code, and it relates to shareholder governance outcomes. The document is short and confirms the minutes are attached, but the content itself *is* the minutes summary, making AGM-R more appropriate than RPA or RNS.
2024-09-17 English
Minutes from Extraordinary General Meeting
AGM Information Classification · 1% confidence The document explicitly details the proceedings of a 'General Meeting,' specifically an 'Extraordinary General Meeting' (EGM). It includes items like the election of the chairman, approval of the agenda, and detailed voting results on key resolutions, such as a 'Share consolidation (reverse split)' and 'Authorization to acquire treasury shares.' The presence of detailed voting tables and minutes strongly indicates this is a record of a shareholder meeting. This aligns perfectly with the definition of AGM Information (AGM-R), although this is an EGM, the structure and purpose are identical to the materials shared during an Annual General Meeting. Therefore, AGM-R is the most appropriate classification.
2024-09-17 English
Minutes from Extraordinary General Meeting
AGM Information Classification · 1% confidence The document explicitly states it contains the "Minutes from Extraordinary General Meeting". An Extraordinary General Meeting (EGM) is a type of general meeting, similar to an AGM. The classification options include 'AGM Information' (AGM-R) for presentations and materials shared during the Annual General Meeting. Since this document contains the official minutes of a general meeting (EGM), it aligns best with the category covering general meeting materials, which is AGM-R. Although it is the minutes (a record) rather than a presentation, it is the most specific category available for general shareholder meeting documentation. The document is short and announces that the complete minutes are attached, but the content provided *is* the summary/record of the meeting outcomes, making it more than just a simple RPA.
2024-09-17 English
LIFE Successfully completes the first patient in the longevity trial after three months
Regulatory Filings Classification · 1% confidence The document is a press release dated September 11, 2024, announcing a specific operational milestone: the successful completion of the first patient (a dog) in a longevity trial for their Continuous Glucose Monitor (CGM) technology. It details the removal of an implant after 12 weeks and plans for further analysis and future patient enrollment. This type of announcement, focusing on clinical trial progress, operational updates, and immediate results, is characteristic of an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category. Since it is an announcement of operational progress rather than a comprehensive financial report (10-K, IR) or a management discussion (MDA), and it is not a transcript (CT) or a formal notice of a meeting/vote (AGM-R, DVA), the most appropriate general category for a significant, timely operational update that isn't a formal financial report is RNS (Regulatory Filings/General Announcement). Given the content is a specific operational update, it is not a Report Publication Announcement (RPA) as it is reporting the *result* of an event, not announcing the *publication* of a separate, attached report. It is too specific for a general Investor Presentation (IP) and lacks the structure of a formal Audit Report (AR). Therefore, RNS is the best fit as a general regulatory/operational announcement.
2024-09-11 English
LIFE Successfully completes the first patient in the longevity trial after three months
Regulatory Filings Classification · 1% confidence The document is a press release dated September 11, 2024, announcing a specific operational milestone: the successful completion of the first patient in a longevity trial for a new CGM sensor. It details the procedure, quotes the CEO and Managing Director, and discusses future steps. This type of announcement, focusing on operational progress, clinical trial updates, or specific business achievements outside of mandatory financial reporting (like 10-K or ER), typically falls under general Regulatory Filings (RNS) or sometimes Investor Presentation (IP) if it were a slide deck. Since it is a news announcement about a trial milestone and not a formal financial report, dividend notice, or management change, RNS is the most appropriate general regulatory category for this type of corporate update that doesn't fit the highly specific financial/governance codes. Given the document length (4746 chars) and content, it is a direct announcement, not just a notice to publish a report (RPA).
2024-09-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.